Tatva Chintan Pharma Chem Limited

🔴 Bear CaseWhat could go wrong?

1. Sales are being booked faster than collected
   Receivables are up 41% against revenue up 19%. If customers keep taking longer to pay, reported profit will not turn into cash — and write-offs follow if some never do.
2. A premium to the sector to defend
   It trades 119% above the peer median. That premium needs a reason that persists, or it closes.
3. Growth barely outpaces inflation
   Revenue compounding at 6.0% a year is close to the rate prices rise, so the business is gaining little ground in real terms. That leaves the share price dependent on a re-rating rather than on earnings growth.
4. Returns on shareholder capital are falling
   ROE has dropped from 8.8% to 5.4%. Each rupee of equity earns less than it did, so profit growth increasingly depends on raising more capital rather than on the existing base working harder.
5. Earnings are hard to forecast
   Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.